The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Post-recurrent survival of a phase III trial comparing adjuvant chemotherapy with docetaxel plus S-1 versus S-1 alone in stage III gastric cancer: A post-hoc analysis of the START-2 trial (JACCRO GC-07).
 
Hiroo Ishida
No Relationships to Disclose
 
Yu Sunakawa
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Guardant Health; Incyte; Lilly Japan; Merck; MSD K.K; Ono Pharmaceutical; Sysmex; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo; MSD K.K
Research Funding - Chugai Pharma; Lilly Japan; Otsuka; Sanofi; Taiho Pharmaceutical; Takeda
 
Yasuhiro Kodera
Honoraria - Abbvie; Amgen; Chugai Pharma; Covidien/Medtronic; Daiichi Sankyo; Lilly Japan; Miyarisan Pharmaceutical; MSD K.K; Nippon Kayaku; Olympus; Ono Pharmaceutical; Taiho Pharmaceutical; Tsumura & Co.; Yakult Honsha
Consulting or Advisory Role - Daii Sankyo
Research Funding - abbott Japan (Inst); Bayer (Inst); Chugai Pharma (Inst); Covidien (Inst); Daiichi Sankyo (Inst); Johnson & Johnson (Inst); Kaken Pharmaceutical (Inst); Lilly Japan (Inst); Merck Serono (Inst); Nippon Kayaku (Inst); Otsuka (Inst); Otsuka (Inst); Sanofi (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); TOA Pharmaceuticals (Inst); Tsumura & Co. (Inst)
 
Kazuhiro Yoshida
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Covidien; Daiichi Sankyo; EA Pharma; Lilly Japan; MSD K.K; Nippon Kayaku; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical; Takeda; TERUMO; Tsumura & Co.; Yakult Honsha
Research Funding - Abbott (Inst); Asahi Kasei (Inst); Chugai Pharma (Inst); Covidien (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EPS Corporation (Inst); EPS Holdings (Inst); Fujifilm (Inst); Johnson & Johnson (Inst); Kaken Pharmaceutical (Inst); Kyowa Kirin (Inst); Lilly Japan (Inst); MSD K.K (Inst); Nippon Kayaku (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Sanofi (Inst); Shift Zero (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TERUMO (Inst); Tsumura & Co. (Inst); Yakult Honsha (Inst)
 
Mitsugu Kochi
No Relationships to Disclose
 
Yoshihiro Kakeji
Honoraria - Chugai Pharma; Daiichi Sankyo; Lilly Japan; MSD; Nippon Kayaku; Ono Pharmaceutical; Taiho Pharmaceutical
 
Takeshi Sano
No Relationships to Disclose
 
Masahiro Takeuchi
No Relationships to Disclose
 
Wataru Ichikawa
Honoraria - AstraZeneca; Bayer Yakuhin; Chugai Pharma; Merck Serono; Nihonkayaku; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Masashi Fujii
Travel, Accommodations, Expenses - Japan Clinical Cancer Research Organization